These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30975150)

  • 1. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings.
    Mesa RA; Su Y; Woolfson A; Prchal JT; Turnbull K; Jabbour E; Scherber R; Shields AL; Krohe M; Ojo F; Pompilus F; Cappelleri JC; Harrison C
    Health Qual Life Outcomes; 2019 Apr; 17(1):61. PubMed ID: 30975150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
    Chen YY; Huang CE; Lee KD; Chen CC
    Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
    Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
    Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
    Mascarenhas J; Harrison C; Schuler TA; Liassou D; Garretson M; Miller TA; Mahadevan S; McBride A; Tang D; DeGutis IS; Abraham P; Kish J; Feinberg BA; Gerds AT
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):122-132. PubMed ID: 37839939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
    Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
    J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the management of myelofibrosis.
    Komrokji RS; Verstovsek S; Padron E; List AF
    Cancer Control; 2012 Oct; 19(4 Suppl):4-15. PubMed ID: 23042420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose ruxolitinib shows effective in treating myelofibrosis.
    Yang Y; Luo H; Zheng Y; Zou Z; Niu T; Jia Y; Zhu H; Liu T; Wu Y; Chang H; Ji J; Li J; Pan L
    Ann Hematol; 2021 Jan; 100(1):135-141. PubMed ID: 33083863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
    Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
    [No Abstract]   [Full Text] [Related]  

  • 12. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
    Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deriving a Preference-Based Measure for Myelofibrosis from the EORTC QLQ-C30 and the MF-SAF.
    Mukuria C; Rowen D; Brazier JE; Young TA; Nafees B
    Value Health; 2015 Sep; 18(6):846-55. PubMed ID: 26409613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.
    Oritani K; Ohishi K; Okamoto S; Kirito K; Komatsu N; Tauchi T; Handa H; Saito S; Takenaka K; Shimoda K; Okada H; Amagasaki T; Wakase S; Shimozuma K; Akashi K
    Curr Med Res Opin; 2018 Mar; 34(3):531-537. PubMed ID: 29224367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for myelofibrosis.
    Atallah E; Verstovsek S
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Patients with Early Myelofibrosis: A Discussion of Best Practices.
    Bose P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):111-119. PubMed ID: 38441783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.
    Harrison CN; Mesa RA; Kiladjian JJ; Al-Ali HK; Gisslinger H; Knoops L; Squier M; Sirulnik A; Mendelson E; Zhou X; Copley-Merriman C; Hunter DS; Levy RS; Cervantes F; Passamonti F; Barbui T; Barosi G; Vannucchi AM
    Br J Haematol; 2013 Jul; 162(2):229-39. PubMed ID: 23672349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
    Scotch AH; Kosiorek H; Scherber R; Dueck AC; Slot S; Zweegman S; Boekhorst PAWT; Commandeur S; Schouten H; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA; Geyer HL
    Leuk Res; 2017 Dec; 63():34-40. PubMed ID: 29096334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical management of patients with myelofibrosis receiving ruxolitinib.
    Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
    Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
    Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV; Winton EF; Natrajan K; Odenike O; Claxton D; Peng W; O'Neill P; Erickson-Viitanen S; Leopold L; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Hematol Oncol; 2013 Oct; 6(1):81. PubMed ID: 24283202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.